Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.

Autor:	Mossong J; Surveillance & Epidemiology of Infectious Diseases, Laboratoire National de Santé, PO Box 1102, L-1011 Luxembourg. joel.mossong@lns.etat.lu, Bill S, Hawotte K, Gilson G, Knolle U, Weber J, Roskams T, Arendt V
Jazyk:	angličtina
Zdroj:	Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg [Bull Soc Sci Med Grand Duche Luxemb] 2011 (1), pp. 19-30.
Abstrakt:	Objective: The aim of our study was to assess the diagnostic performance of various serological markers and scores for predicting significant fibrosis retrospectively in a population of patients referring to our hospital for liver biopsy and chronic hepatitis C. Materials and Methods: Stored serum obtained from 186 patients were tested for a number of biological markers putatively associated with liver fibrosis. Fibrotest and Forns scores were compared with liver fibrosis pathology scored according to the METAVIR system by multiple logistic regression. Results: The prevalence of significant fibrosis was 44%. Aspartate amino transferase (AST) and gamma-glutamyltransferase (GGT) were most correlated with METAVIR staging, followed by platelet counts and alpha2-macroglobulin. The negative predictive value was 77% and 83% and the positive predictive value was 100% and 84% for the Forns score and the Fibrotest, respectively. In multivariate analysis AST, GGT and alpha2-macroglobulin had independent predictive power. Conclusions: The accuracy of serological markers in predicting significant fibrosis is limited, because approximately two thirds of patients lie into an indeterminate "grey zone". Serological markers might be useful for patients reluctant to undergo liver biopsy but current predictive scoring systems are too inaccurate to replace biopsies in a routine manner.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu